MN-C.H.-ROBINSON
Global logistics company C.H. Robinson announced its recognition as a Challenger in the new Gartner Magic Quadrant for Real-Time Transportation Visibility Platforms* (RTTVP) . Faced with multiple disruptions from the global pandemic, trade and tariff disputes, severe weather, capacity shortages, and a trade lane blockage, shippers are prioritizing and investing in RTTVP solutions like C.H. Robinson’s Navisphere Vision to improve their resiliency, connectivity, and performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005194/en/
Gartner, the world’s leading research and advisory company that publishes the annual series of market data known as Magic Quadrant, reports “the RTTVP market doubled in size in North American in 2020. This growth was accelerated due to the supply chain disruptions created by the pandemic.”
Navisphere Vision, delivered by TMC, a division of C.H. Robinson , helps shippers track, monitor, and respond to supply chain disruptions on a global scale. As a software-as-a-service (SaaS) platform, Navisphere Vision connects and pulls data from shippers’ third-party providers, carriers, and suppliers—plus weather, traffic, and geopolitical monitoring sources—to deliver real-time visibility and insights to inventory at-rest or in-motion, across all modes and regions. With Navisphere Vision’s Internet of Things (IoT) device integrations, customers can monitor and immediately mitigate issues when shipments are impacted by shock, tilt, humidity, light, temperature, or pressure.
“Several major events over the past year have emphasized the vital importance of supply chains, but also highlighted their fragility in some cases,” said Jordan Kass, president of TMC. “The companies who will excel in the years to come will be those with real-time visibility into their supply chains. The ability to consume, combine and analyze data from growing number of integrations and data points will be essential for building a resilient, competitive, and profitable supply chain.”
C.H. Robinson (TMC) was also recognized as a Challenger in the 2021 Gartner Magic Quadrant for Transportation Management Systems.
“We believe these recognitions reinforce the power of our innovative technology, built by and for supply chain experts, backed by the experience and scale of one of the world’s most-connected platforms,” said Kass.
To expand on these capabilities, the company previously announced a commitment to invest $1 billion in technology over the next five years, doubling its previous investment.
A complimentary copy of the Magic Quadrant for Real-Time Transportation Visibility Platforms is available here .
* Gartner, Magic Quadrant for Real-Time Transportation Visibility Platforms, Bart De Muynck, Carly West, 14 April 2021
Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advice technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About C.H. Robinson
C.H. Robinson solves logistics problems for companies across the globe and across industries, from the simple to the most complex. With $21 billion in freight under management and 19 million shipments annually, we are one of the world’s largest logistics platforms. Our global suite of services accelerates trade to seamlessly deliver the products and goods that drive the world’s economy. With the combination of our multi-modal transportation management system and expertise, we use our information advantage to deliver smarter solutions for our more than 105,000 customers and 73,000 contract carriers. Our technology is built by and for supply chain experts to bring faster, more meaningful improvements to our customers’ businesses. As a responsible global citizen, we are also proud to contribute millions of dollars to support causes that matter to our company, our Foundation and our employees. For more information, visit www.chrobinson.com (Nasdaq: CHRW).
About TMC, a division of C.H. Robinson
Global supply chains are growing increasingly complex. Businesses need the latest technology and industry expertise to advance and stay ahead of the competition. At TMC, a division of C.H. Robinson, we understand what makes supply chains faster, stronger, and more efficient. As a leader in global logistics management, we combine industry expertise with our global technology platform, Navisphere®, to support the world’s most complex supply chains. Our logistics experts are located in Control Tower® locations around the world: Amsterdam, Chicago, Monterrey, São Paulo, Seattle, Shanghai, and Wrocław. This Control Tower® network, supported by our technology platform, connects our customers to their suppliers and supply chain partners. Our customers leverage these capabilities to manage their logistics in over 170 countries across all modes of transportation. For more information, visit www.mytmc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005194/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom